Nebraska

OMAHA, Nebraska, March 7, 2011 - InterCall, a subsidiary of West Corporation and the world's largest conferencing and collaboration services provider, today announced the acquisition of Unisfair, a leading global provider of virtual events and business environments.

ARMONK, New York and OMAHA, Nebraska - IBM (NYSE: IBM) today announced a collaboration with Metropolitan Community College (MCC) in Omaha, Nebraska, to develop a first-of-its-kind green data center management degree using IBM hardware, software and online skills training resources.

PEMBROKE, Bermuda - Allied World Assurance Company Holdings, Ltd (NYSE: AWH) today announced that Ralph Rathjen, Chief Risk Officer, will be participating in a panel at Aon Benfield's ERM and Capital Modeling Conference in Chicago on May 27, 2009.

BASEL, Switzerland - **This press release is not intended for the UK media** - Once daily QAB149 (indacaterol) significantly improves lung function compared to formoterol and tiotropium, two currently approved COPD treatments, at three months of treatment[1,2] - Pending approval, QAB149 could be the first once-daily bronchodilator to combine clinically relevant 24-hour bronchodilation with onset of action within five minutes[3,4,5] - All doses of QAB149 are well-tolerated with a good overall safety profile in three pivotal trials: INVOLVE (1 year), INHANCE (6 months) and INLIGHT-1 (3 months)[4,5,6] - COPD, a debilitating and progressive respiratory disease, is a leading and growing cause of death that affects 210 million people worldwide[7] BASEL, Switzerland, May 21 /PRNewswire/ -- Initial results from three pivotal phase III trials show the Novartis investigational bronchodilator QAB149 (indacaterol) could deliver clinically relevant[*] lung function improvements, within five minutes of the first dose, lasting for 24 hours in patients with chronic obstructive pulmonary disease (COPD)[3,4,5].